ATE55151T1 - Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen. - Google Patents

Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen.

Info

Publication number
ATE55151T1
ATE55151T1 AT84300091T AT84300091T ATE55151T1 AT E55151 T1 ATE55151 T1 AT E55151T1 AT 84300091 T AT84300091 T AT 84300091T AT 84300091 T AT84300091 T AT 84300091T AT E55151 T1 ATE55151 T1 AT E55151T1
Authority
AT
Austria
Prior art keywords
yeast
synthesis
expression systems
foreign proteins
containing vectors
Prior art date
Application number
AT84300091T
Other languages
English (en)
Inventor
Rae Lyn Burke
Olson Patricia Tekamp
Steven Rosenberg
Pablo D T Valenzuela
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23860419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE55151(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE55151T1 publication Critical patent/ATE55151T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Toys (AREA)
  • Peptides Or Proteins (AREA)
AT84300091T 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen. ATE55151T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46858983A 1983-02-22 1983-02-22
EP84300091A EP0120551B1 (de) 1983-02-22 1984-01-06 Expressionssysteme für Hefe mit einen GAPDH Promotor enthaltenden Vektoren und Synthese von Fremdproteinen

Publications (1)

Publication Number Publication Date
ATE55151T1 true ATE55151T1 (de) 1990-08-15

Family

ID=23860419

Family Applications (3)

Application Number Title Priority Date Filing Date
AT84300091T ATE55151T1 (de) 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen.
AT91114001T ATE138975T1 (de) 1983-02-22 1984-01-06 Expressionssysteme für hefe mit vektoren, die einen gapdh-promotor enthalten und oberflächenantigensynthese von hepatitis b
AT89106868T ATE93894T1 (de) 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit pyk-promotoren enthaltenden vektoren und synthese von fremdproteinen.

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT91114001T ATE138975T1 (de) 1983-02-22 1984-01-06 Expressionssysteme für hefe mit vektoren, die einen gapdh-promotor enthalten und oberflächenantigensynthese von hepatitis b
AT89106868T ATE93894T1 (de) 1983-02-22 1984-01-06 Expressionssysteme fuer hefe mit pyk-promotoren enthaltenden vektoren und synthese von fremdproteinen.

Country Status (7)

Country Link
EP (4) EP0460716B2 (de)
JP (2) JPS59210888A (de)
AT (3) ATE55151T1 (de)
CA (2) CA1341302C (de)
DE (3) DE3486431T3 (de)
DK (1) DK173604B1 (de)
SG (1) SG48422A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
JPS5931799A (ja) * 1982-08-16 1984-02-20 Science & Tech Agency B型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
JPS5936699A (ja) * 1982-08-20 1984-02-28 Chemo Sero Therapeut Res Inst シヤトルベクタ−
US5422267A (en) * 1984-05-22 1995-06-06 Robert R. Yocum Industrial yeast comprising an integrated glucoamylase gene
EP0173997A1 (de) * 1984-09-06 1986-03-12 Chiron Corporation Katzenleukämievirusproteinimpfstoffe und ihre Herstellung
CA1339912C (en) * 1984-12-06 1998-06-16 Jacques Oberto Transformed yeasts producing lysozyme, plasmids used for this transformation, and uses thereof
EP0211767B1 (de) * 1985-08-05 1991-03-06 Merck & Co. Inc. Verfahren zur Steigerung der Produktion von rekombinantem Protein in Hefearten der Gattung Saccharomyces
ES2028779T3 (es) * 1985-10-03 1992-07-16 Green Cross Corporation Promotor de levadura y procedimiento para preparar proteina heterologa.
JPH0655155B2 (ja) * 1985-10-03 1994-07-27 株式会社ミドリ十字 蛋白質の製造方法
DK162900C (da) * 1985-10-24 1992-05-11 Danisco Fremgangsmaade til ekspression af gener i gaer samt dna-fragment, rekombineret dna-segment og plasmider, hvor disse indgaar til brug ved udoevelse af fremgangsmaaden
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
JPS62236496A (ja) * 1986-04-07 1987-10-16 Green Cross Corp:The HBsAgの製造方法
US4839283A (en) * 1986-12-30 1989-06-13 Zymogenetics, Inc. Method of expressing alpha-1-antitrypsin in yeast
ATE207535T1 (de) * 1987-06-22 2001-11-15 Medeva Holdings Bv Hepatitis-b-oberflächenantigen enthaltendes peptid
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
AU644619B2 (en) 1989-12-21 1993-12-16 Advanced Technologies (Cambridge) Limited Modification of plant metabolism
NZ236434A (en) * 1990-01-29 1992-08-26 Ciba Geigy Ag Dna molecules comprising the a niger pyruvate kinase transcription promoter, vectors containing it and their use in transforming host cells
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
EP0785273A1 (de) 1990-11-26 1997-07-23 Genetics Institute, Inc. Gepaarte basische Aminosäuren konvertierendes Enzym und dafür kodierende DNA Sequenz
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
WO1994026306A1 (en) 1993-05-12 1994-11-24 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
JPH08173170A (ja) * 1994-05-25 1996-07-09 Kirin Brewery Co Ltd キャンディダ・ユティリス酵母の形質転換系、およびそれによる異種遺伝子の発現
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
ES2229288T3 (es) 1995-12-22 2005-04-16 Dsm Ip Assets B.V. Metodos mejorados para transformar cepas de phaffia, cepas de phaffia transformadas asi obtenidas y dna recombinante en dichos metodos.
JP4472866B2 (ja) 1997-11-06 2010-06-02 カイロン ソチエタ ア レスポンサビリタ リミタータ ナイセリア抗原
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
US6087128A (en) * 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
DK1093517T3 (da) 1998-05-01 2008-06-23 Novartis Vaccines & Diagnostic Neisseria-meningitidis-antigener og præparater
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP2275553B1 (de) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Antigenpeptide aus Neisseria
US6709863B2 (en) 1999-12-08 2004-03-23 Iowa State University Research Foundation Nucleic acid molecules encoding multiple start codons and histidine tags
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
ES2330083T3 (es) 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
US7838287B2 (en) 2001-01-25 2010-11-23 Evolva Sa Library of a collection of cells
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CN100515494C (zh) 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
EP1572720A4 (de) 2002-05-24 2008-12-24 Nps Allelix Corp Verfahren zur enzymatischen herstellung von glp-2-(1-33)- und glp-2-(1-34)-peptiden
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CA2546319A1 (en) 2003-11-21 2005-07-28 Nps Allelix Corp. Production of glucagon like peptide 2 and analogs
DE10356218A1 (de) * 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
WO2005074546A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
NZ582684A (en) 2004-06-18 2011-05-27 Ambrx Inc Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
CA2590590C (en) 2004-12-22 2016-04-19 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
ES2443529T3 (es) 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh Vacunación múltiple incluyendo meningococo del serogrupo C
EP1951890A4 (de) 2005-11-16 2009-06-24 Ambrx Inc Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
JP2009519942A (ja) 2005-12-14 2009-05-21 アンブルックス,インコーポレイテッド 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
CN104193815A (zh) 2006-09-08 2014-12-10 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
ES2457527T3 (es) 2006-09-08 2014-04-28 Ambrx, Inc. ARNt Supresor hibrido en células de vertebrados
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 fgf-21 폴리펩티드 및 그 용도
WO2008139591A1 (ja) * 2007-05-11 2008-11-20 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 組換えアプロチニンの生産方法
EP2930182A1 (de) 2007-11-20 2015-10-14 Ambrx, Inc. Modifizierte insulinpolypeptide und deren verwendungen
EP3103880A1 (de) 2008-02-08 2016-12-14 Ambrx, Inc. Modifizierte leptinpolypeptide und deren verwendungen
AU2009274076C1 (en) 2008-07-23 2014-04-17 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
BR112012015461A2 (pt) 2009-12-21 2017-01-10 Ambrx Inc polipeptídeos de somatotropina boviina modificados e seus usos
WO2011087810A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
US9476082B2 (en) 2010-05-20 2016-10-25 Evolva Sa Method of producing isoprenoid compounds in yeast
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2742296T3 (es) 2010-08-17 2020-02-13 Ambrx Inc Polipéptidos de relaxina modificados y sus usos
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
KR102670432B1 (ko) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
GR76274B (de) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
CA1224735A (en) * 1982-05-19 1987-07-28 Cornelius P. Hollenberg Cloning system for kluyveromyces species
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
JPH0716432B2 (ja) * 1982-10-20 1995-03-01 サントリー株式会社 酵母の高発現ベクタープラスミドを用いたペプチドの生産方法

Also Published As

Publication number Publication date
EP0120551A2 (de) 1984-10-03
EP0329203B1 (de) 1993-09-01
EP0329203A1 (de) 1989-08-23
DE3486206T2 (de) 1994-02-03
EP0120551B1 (de) 1990-08-01
DK173604B1 (da) 2001-04-23
DE3486431T3 (de) 2000-05-04
EP0460716A1 (de) 1991-12-11
EP0120551A3 (en) 1986-05-14
DE3486206D1 (de) 1993-10-07
EP0460716B1 (de) 1996-06-05
CA1341302C (en) 2001-10-09
DE3486431T2 (de) 1996-10-10
SG48422A1 (en) 1998-04-17
JPH0724594B2 (ja) 1995-03-22
EP0732403A1 (de) 1996-09-18
EP0460716B2 (de) 1999-12-15
ATE138975T1 (de) 1996-06-15
JPH05268984A (ja) 1993-10-19
CA1341116C (en) 2000-10-17
DK577783A (da) 1984-08-23
DE3486431D1 (de) 1996-07-11
JPH0515431B2 (de) 1993-03-01
DE3482844D1 (de) 1990-09-06
DK577783D0 (da) 1983-12-15
ATE93894T1 (de) 1993-09-15
JPS59210888A (ja) 1984-11-29

Similar Documents

Publication Publication Date Title
ATE55151T1 (de) Expressionssysteme fuer hefe mit einen gapdh promotor enthaltenden vektoren und synthese von fremdproteinen.
EP1245678A3 (de) Rekombinante Proteine von mit Lymphadenopathiesyndrom und/oder erworbenem Immunschwächesyndrom assoziierten Viren
AU6733487A (en) Mammalian interleukin-4
ES8402351A1 (es) Procedimiento para producir interferon inmune humano.
HK26684A (en) Purified proteins and process therefor
ES2123006T3 (es) Levaduras recombinantes altamente estables para la produccion de proteinas recombinantes.
ES8603957A1 (es) Procedimiento para obtener una proteina heterologa para levadura
ES8605039A1 (es) Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos.
ATE173275T1 (de) Von einem retrovirus aus der hiv-gruppe abgeleitete peptide und deren verwendung
DE68928380D1 (de) Expression von menschlichen Serumalbumin in methylotrophischen Hefen
DK27885A (da) Fremstilling af peptider
EP0291728A3 (de) Herstellung von Immun-Interferon und seiner m-RNS
DE3485444D1 (de) Hybrid-dns-synthese von insulin.
ES8505253A1 (es) Un procedimiento para preparar un organismo unicelular que tiene una secuencia de adn que codifica un plipeptid0 que tiene un determinante inmunorreactivo u antigeno de una glicoproteina de virus de herpes simplex.
ES2065915T3 (es) Procedimiento para aumentar la expresion de polipeptidos en un cultivo de celula recombinante.
AU7378087A (en) Interleukin-2 induced antineoplastic peptide
ATE93893T1 (de) Expressionssysteme zur ueberproduktion gewuenschter proteine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time